SG11201809252YA - Methods for determining dpp3 and therapeutic methods - Google Patents
Methods for determining dpp3 and therapeutic methodsInfo
- Publication number
- SG11201809252YA SG11201809252YA SG11201809252YA SG11201809252YA SG11201809252YA SG 11201809252Y A SG11201809252Y A SG 11201809252YA SG 11201809252Y A SG11201809252Y A SG 11201809252YA SG 11201809252Y A SG11201809252Y A SG 11201809252YA SG 11201809252Y A SG11201809252Y A SG 11201809252YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- pct
- dpp3
- determining
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111 0111010101111101011111011101111101011111111111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/182561 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, G01N 33/68 (2006.01) A61K 39/395 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, GO1N 33/574 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (21) International Application Number: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, PCT/EP2017/059377 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 20 April 2017 (20.04.2017) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 16166476.8 21 April 2016 (21.04.2016) EP TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: SPHINGOTEC THERAPEUTICS GMBH [DE/DE]; Neuendorfstrasse 15A, 16761 Hennigsdorf (DE). Published: (72) Inventor: BERGMANN, Dr. Andreas; Am Rosenanger — with international search report (Art. 21(3)) 78, 13465 Berlin (DE). — with amended claims (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a)) (74) Agent: BOEHMERT & BOEHMERT; Dr. Ute Kilger, Hollerallee 32, 28209 Bremen (DE). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, =_ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (54) Title: = Mg. 2 A: = 55- = - = 45- = = 40 = = 35 E = •D o n. 26- li 20 • li V; N ot 1-1 IN li 5 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS ocu . * . . . . . ] p ‹ 0.005 (57) : The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or pre- venting said disease. © Norm F MI Sepsis Cancer AKI LRTI N C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16166476 | 2016-04-21 | ||
PCT/EP2017/059377 WO2017182561A1 (en) | 2016-04-21 | 2017-04-20 | Methods for determining dpp3 and therapeutic methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809252YA true SG11201809252YA (en) | 2018-11-29 |
Family
ID=56014788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809252YA SG11201809252YA (en) | 2016-04-21 | 2017-04-20 | Methods for determining dpp3 and therapeutic methods |
Country Status (14)
Country | Link |
---|---|
US (2) | US20190145981A1 (en) |
EP (3) | EP3854817A1 (en) |
JP (3) | JP2019520550A (en) |
KR (2) | KR102565453B1 (en) |
CN (1) | CN110168372A (en) |
AU (2) | AU2017252212B2 (en) |
BR (1) | BR112018071583A2 (en) |
CA (1) | CA3021252A1 (en) |
CH (1) | CH713803B1 (en) |
DE (1) | DE112017002105T5 (en) |
IL (1) | IL262472A (en) |
MX (2) | MX2018012856A (en) |
SG (1) | SG11201809252YA (en) |
WO (1) | WO2017182561A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020006563A2 (en) | 2017-10-25 | 2020-10-13 | 4TEEN4 Pharmaceuticals GmbH | binder for dpp3 targeted to, and that binds to specific dpp3 epitopes and their use in preventing or treating acute diseases / conditions that are associated with oxidative stress |
EP3897686A2 (en) * | 2018-12-21 | 2021-10-27 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
US20230193348A1 (en) | 2020-02-27 | 2023-06-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
EP4110812A2 (en) | 2020-02-27 | 2023-01-04 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
JP2023518731A (en) | 2020-03-16 | 2023-05-08 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | DPP3 in patients infected with coronavirus |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JPS6188884A (en) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | Encephalinase b-inhibiting substance and its preparation |
AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2087997T3 (en) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES. |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH06219989A (en) * | 1993-01-27 | 1994-08-09 | Microbial Chem Res Found | New physiologically active substances fluostatin a and b, their production and use thereof |
US5612186A (en) | 1994-06-22 | 1997-03-18 | Food Industry Research And Development Institute | Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples |
US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6872560B1 (en) | 1999-09-01 | 2005-03-29 | Incyte Corporation | Human hydrolytic enzymes |
AU2002225954A1 (en) * | 2000-11-08 | 2002-05-21 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
JP2005508623A (en) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | Modified transferrin fusion protein |
DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
CN1852974A (en) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | Compositions and methods for treating and diagnosing cancer |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
WO2005106486A2 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
CN1961077A (en) * | 2004-06-01 | 2007-05-09 | 希森美康株式会社 | Method for measuring enzyme activity and column for use in measuring enzyme activity |
EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
JP2006230318A (en) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | Method for diagnosing rheumatoid arthritis |
CN100420947C (en) * | 2005-05-30 | 2008-09-24 | 孙东旭 | Method for quantitative determination of specific analyte with single trapping agent and reagent kit therefor |
KR101376471B1 (en) | 2006-03-13 | 2014-03-27 | 백톤 디킨슨 앤드 컴퍼니 | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
WO2007146229A2 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
US8715928B2 (en) * | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
WO2011073209A1 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
KR101234352B1 (en) * | 2010-03-18 | 2013-02-15 | 권동락 | A selective cytapheresis apparatus |
HUE043835T2 (en) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Tear lipocalin muteins binding il-4 r alpha |
-
2017
- 2017-04-20 SG SG11201809252YA patent/SG11201809252YA/en unknown
- 2017-04-20 AU AU2017252212A patent/AU2017252212B2/en active Active
- 2017-04-20 WO PCT/EP2017/059377 patent/WO2017182561A1/en active Application Filing
- 2017-04-20 EP EP21153574.5A patent/EP3854817A1/en active Pending
- 2017-04-20 KR KR1020187033194A patent/KR102565453B1/en active IP Right Grant
- 2017-04-20 CA CA3021252A patent/CA3021252A1/en active Pending
- 2017-04-20 KR KR1020237026743A patent/KR20230123520A/en active Application Filing
- 2017-04-20 JP JP2018555652A patent/JP2019520550A/en active Pending
- 2017-04-20 EP EP21153560.4A patent/EP3896450A1/en active Pending
- 2017-04-20 MX MX2018012856A patent/MX2018012856A/en unknown
- 2017-04-20 BR BR112018071583-2A patent/BR112018071583A2/en unknown
- 2017-04-20 DE DE112017002105.7T patent/DE112017002105T5/en active Pending
- 2017-04-20 US US16/095,563 patent/US20190145981A1/en active Pending
- 2017-04-20 EP EP17720047.4A patent/EP3446125A1/en active Pending
- 2017-04-20 CN CN201780039077.1A patent/CN110168372A/en active Pending
- 2017-04-20 CH CH001280/2018A patent/CH713803B1/en not_active IP Right Cessation
-
2018
- 2018-10-18 IL IL262472A patent/IL262472A/en unknown
- 2018-10-19 MX MX2020001193A patent/MX2020001193A/en unknown
-
2020
- 2020-04-23 JP JP2020076521A patent/JP7219737B2/en active Active
- 2020-07-02 US US16/919,449 patent/US11726094B2/en active Active
-
2022
- 2022-07-08 JP JP2022110620A patent/JP2022163014A/en active Pending
-
2023
- 2023-11-02 AU AU2023258417A patent/AU2023258417A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018140832A3 (en) | 2020-08-14 |
CH713803B1 (en) | 2023-08-15 |
RU2018140832A (en) | 2020-05-21 |
JP2020127409A (en) | 2020-08-27 |
JP2019520550A (en) | 2019-07-18 |
US20200378977A1 (en) | 2020-12-03 |
CA3021252A1 (en) | 2017-10-26 |
EP3896450A1 (en) | 2021-10-20 |
CN110168372A (en) | 2019-08-23 |
AU2017252212B2 (en) | 2023-09-07 |
KR102565453B1 (en) | 2023-08-11 |
IL262472A (en) | 2018-12-31 |
EP3446125A1 (en) | 2019-02-27 |
KR20230123520A (en) | 2023-08-23 |
AU2023258417A1 (en) | 2023-11-23 |
US11726094B2 (en) | 2023-08-15 |
DE112017002105T5 (en) | 2019-04-25 |
JP2022163014A (en) | 2022-10-25 |
JP7219737B2 (en) | 2023-02-08 |
AU2017252212A1 (en) | 2018-11-08 |
EP3854817A1 (en) | 2021-07-28 |
KR20190003959A (en) | 2019-01-10 |
MX2020001193A (en) | 2020-03-20 |
WO2017182561A1 (en) | 2017-10-26 |
US20190145981A1 (en) | 2019-05-16 |
BR112018071583A2 (en) | 2019-02-12 |
MX2018012856A (en) | 2019-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201909656YA (en) | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408347UA (en) | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201407561UA (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201908980PA (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201809473QA (en) | Humanized anti-basigin antibodies and the use thereof |